Propagating factor IX-producing hepatocytes for haemophilia B therapy

Thrombosis and Haemostasis

Volumn 99, Issue 5, 2008, Pages 799-800

  Ofosu, Frederick A ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9;

BLOOD TRANSFUSION; EDITORIAL; HEMOPHILIA B; HEPATOCYTE TRANSPLANTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER TRANSPLANTATION; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELL TRANSPLANTATION; CELLS, CULTURED; DOGS; FACTOR IX; HEMOPHILIA B; HEPATOCYTES; HUMANS; LIVER; MICE; MICE, SCID; MICE, TRANSGENIC; SERUM ALBUMIN; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; URINARY PLASMINOGEN ACTIVATOR;

EID: 43949100659     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-04-0200     Document Type: Editorial

References (15)

1. Roberts HR, Eberst ME. Current management of hemophilia B. Hematol/Oncol Clin North Am 1993; 7: 1269-1280.
2. Nathwani AC, Davidoff AM, Tuddenham EG. Prospects for gene therapy of haemophilia. Haemophilia 2005; 10: 309-318.
3. Wang L, Takabe K, Bidlingmaier SM, et al. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci USA 1999; 96: 2906-3910.
4. Kay MA, Rothenberg S, Landen CN, et al. In vivo gene therapy of hemophilia B: Sustained partial correction in factor IX deficient dogs. Science 1993; 262: 177-119.
5. Herzog RW, Yang EY, Couto LB, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated vira vector. Nat Med 1999; 5: 56-63.
6. Park F, Ohashi K, Kay MA. Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver. Blood 2000; 96: 1173-1176.
7. Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscles in patients with severe hemophilia B. Blood 2003; 101: 2963-2972.
8. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by host immune response. Nat Med 2006; 12: 342-347.
9. Nathwani AC, Davidoff A, Hanawa H, et al. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing human factor IX cDNA. Blood 2001; 97: 1258-1265.
10. Ashrani AA, Reding MT, Shet A, et al. Successful liver transplantation in a patient with severe haemophilia A and a high-titre inhibitor. Haemophilia 2004; 10: 735-737.
11. Wilde J, Teixeira P, Bramhall SR, et al. Liver transplantation in haemophilia. Br J Haematol 2002; 117: 952-956.
12. Gordon FH, Mistry PK, Sabin CA, et al. Outcome of orthotopic liver transplantation in patients with haemophilia. Gut 1998; 42: 755-749.
13. Dhawan A, Mitry RR, Hughes RD, et al. Hepatocyte transplantation for inherited factor VII deficiency. Transplantation 2004; 78: 1812-1814.
14. Ohashi K, Waugh JM, Dake MD, et al. Liver tissue engineering at extra hepatic sites in mice as a potential new therapy for genetic liver diseases. Hepatology 2005; 41: 132-140.
15. Tatsumi K, Ohashi K, Miho K, et al. Successful in vivo propagation of factor IX-producing hepatocytes in mice: potential cell therapy in haemophilia B. Thromb Haemost 2008; 99: 883-891.